Abstract

The novel optically pure compounds, i.e. the single enantiomeric compounds, (+)-5-fluoro-2-[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and (-)-5-fluoro-2-[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or a therapeutically acceptable salt thereof, such as Na^+, Mg^{2+}, Li^+, K^+, Ca^{2+} and $N^+(R)_4$ salts, where R is an alkyl group with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.